News · Brain & Mental Health
An antibody blocking B12 from reaching the brain was found in over half of unexplained spinal cord cases
Idiopathic myelopathy means the spinal cord is failing and nobody knows why. Testing 32 such patients turned up an autoantibody against the receptor that carries vitamin B12 into cells, in 18 of them.
- An antibody against the B12 transport receptor showed up in 18 of 32 patients.
- All of them had spinal cord disease with no known cause.
- Active B12 in the spinal fluid was lower in those who tested positive.
- Blood B12 can look normal while the brain and cord are short of it.
- A small discovery cohort, so this needs confirming before it becomes a test.
Idiopathic is the word medicine uses when it has run out of answers. A patient’s spinal cord is failing, the scans and the blood work and the spinal fluid have all been examined, and nothing explains it. The label describes the doctors rather than the disease.
Writing in JAMA Neurology, researchers took 32 such patients and looked for something nobody had thought to test for. Autoantibodies targeting the transcobalamin receptor turned up in 18 of them.
What the receptor does
Vitamin B12 does not simply diffuse into cells. It is carried through the blood bound to a protein and handed over at a receptor called CD320, which is the door.
Block the door and the arithmetic changes completely. The vitamin is present in the blood in normal amounts, so every standard test reads normal, while the cells that need it are starving.
That distinction is the whole finding. B12 deficiency from poor diet or poor absorption is a supply problem and shows up on a blood test. This would be a delivery problem, and it would not.
The measurement that supports it
An antibody found in patients is suggestive. An antibody found in patients that also does what it should biochemically is much more than that.
Bioactive vitamin B12 concentration was decreased in the spinal fluid of antibody-positive individuals compared with controls who had other neurological diseases, at roughly 15 against 23 units.
So the patients carrying the antibody had less usable B12 where it matters, in the fluid bathing the brain and spinal cord. The mechanism predicts the measurement, and the measurement arrived.
Why B12 and the spinal cord specifically
The connection is old and well described. Severe B12 deficiency produces subacute combined degeneration, in which specific columns of the spinal cord lose their myelin, causing exactly the pattern of numbness, unsteadiness and weakness these patients had.
B12 is one of the B vitamins the body uses to build and maintain the nervous system, and the cord is where a shortage shows first and worst.
A disease that looks like B12 deficiency of the spinal cord, in patients whose blood B12 is normal, is precisely what an antibody against the transport receptor would produce.
What 32 patients cannot establish
This is a discovery cohort, and the word discovery is carrying real weight.
Fifty-six percent sounds decisive and rests on 18 people. The study does not establish how common the antibody is in the wider population of unexplained spinal cord disease, how often it appears in people without symptoms, or whether it predicts anything about how a patient does.
Nor does it test treatment, which is the question every patient will ask. High-dose B12 and immune suppression are both obvious candidates and neither has been tried in this group in any organized way.
Why it matters anyway
Rare-disease findings usually earn a paragraph, and this one deserves more for a specific reason: it converts a diagnosis of exhaustion into a testable hypothesis.
Patients with idiopathic myelopathy typically undergo years of investigation, accumulate no answer, and are managed symptomatically. A blood test for an antibody, if this holds up, replaces that with a name and a mechanism.
Whether it also replaces it with a treatment is the next study, not this one. But the sequence in medicine almost always runs mechanism first, and this is the mechanism.
People also ask
What did the study find?
Autoantibodies targeting the transcobalamin receptor (CD320), responsible for cellular transport of vitamin B12, were identified in 18 of 32 individuals with idiopathic myelopathy (56%) in a discovery cohort. Bioactive vitamin B12 in cerebrospinal fluid was lower in antibody-positive individuals than in controls with other neurological diseases (mean 15.1 vs 22.9 pmol/L; P = .03).
What is idiopathic myelopathy?
Disease of the spinal cord with no identified cause. It can produce weakness, numbness, unsteadiness and bladder problems, and patients often go through extensive testing that finds nothing.
What does CD320 do?
It is the receptor cells use to take up vitamin B12 from the blood. An antibody blocking it would leave B12 circulating normally while the cells that need it, including in the nervous system, go short.
So a normal blood test would miss this?
That is the point of the finding. If the problem is transport into cells rather than supply, blood B12 can read normal while the central nervous system is deficient, which is why the spinal fluid measurement matters.
Is this treatable?
The study does not test treatment. High-dose B12 and immune-directed therapy are the obvious candidates to investigate, and neither is established for this. Nobody should self-treat on the strength of a discovery study.
How confident can we be?
It is a discovery cohort of 32 people. That is enough to establish that the antibody exists in this population and not enough to say how often, how specifically, or what it predicts.
What would someone with unexplained spinal cord disease do?
Nothing yet; the test is not clinically available. It is a reasonable thing to ask a neurologist about as the work develops. This is general information rather than medical advice.